Candel Therapeutics, Inc. (CADL) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 9 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for CADL is $15.00, representing a +194.1% upside from the current price of $5.1. Price targets range from a low of $15.00 to a high of $15.00.
